Alkem Laboratories Ltd revealed a cyberattack on its U.S.-based subsidiary, Enzene Biosciences, resulting in fraudulent fund transfers. The company is actively investigating the incident and prioritizing transparency with regulators and stakeholders.
Affected: Enzene Biosciences, Alkem Laboratories Ltd
Affected: Enzene Biosciences, Alkem Laboratories Ltd
Keypoints
- Cybercriminals compromised business email accounts at Enzene Biosciences’ U.S. operations.
- The attack led to a fraudulent transfer of funds, with the total amount still under investigation.
- Alkem has engaged independent cybersecurity firms to conduct a thorough forensic investigation.
- The company emphasized transparency and adherence to good governance principles in disclosing the breach.
- This incident highlights the rising risk of Business Email Compromise (BEC) attacks in the pharmaceutical sector.
Read More: https://thecyberexpress.com/enzene-biosciences-cyberattack/